Fibroblast activation protein-a (FAP) is a cell surface serine protease expressed at sites of tissue remodeling in embryonic development. FAP is not expressed by mature somatic tissues except activated melanocytes and fibroblasts in wound healing or tumor stroma. FAP expression is specifically silenced in proliferating melanocytic cells during malignant transformation. To study the role of FAP as a tumor suppressor, the gene for mouse fap was cloned and mutated at the catalytic domain (FAP serine mutant, FSM). We found that expression of FAP or FSM at physiologic levels in mouse melanoma cells abrogated tumorigenicity. Remarkably, the mutant form FSM lacking specific serine protease activity was a more potent tumor suppressor. Tumor rejection was not due to adaptive immune responses because RAG1À/À mice challenged with melanoma cells expressing either FAP or FSM were not tumorigenic. In in vitro assays, FAP or FSM expression restored contact inhibition, led to cell cycle arrest at G0/G1 phase, and increased susceptibility to stress-induced apoptosis. Cell death in FAP þ or FSM þ melanoma cells was readily triggered by depletion of survival factors from the media, leading to subsequent activation of caspases via the intrinsic pathway. These results show that expression of FAP is a tumor suppressor that abrogates tumorigenicity through regulation of cell growth and survival.
Introduction
Genes encoding cell surface peptidases (i. e., membrane metalloproteases) have historically been categorized as tumor-promoting genes (Hofmann et al., 2000) . In contrast, we have described a cell surface peptidase, dipeptidyl peptidase IV (DPPIV) that seemed to have tumor-suppressor activity (Wesley et al., 1999) . This glycoprotein was identified as a marker that disappeared during malignant transformation of melanocytes (Houghton et al., 1988; Morrison et al., 1993) . Expression of DPPIV on human melanoma cells at physiologic levels (expressed by normal melanocytes) led to suppression of the malignant phenotype and, notably, also rescued the expression of FAP. FAP and DPPIV each form homodimers, but also can form heterodimers. Fap expression is tightly regulated and is only detected in early development in mesenchyme during tissue remodeling (Niedermeyer et al., 2001) , wound healing and in tumor stroma of epithelial cancers (Garin-Chesa et al., 1990; Rettig et al., 1993; Scanlan et al., 1994) . Whether the tumor-suppressor activity is dependent on DPPIV or FAP expression, or both, is unanswered.
Previous studies have suggested that FAP encodes tumor-suppressor activity, although without direct evidence (Rettig et al., 1993; Tsujimoto et al., 1999; Wesley et al., 1999) . In the melanocytic lineage, primary and metastatic human melanomas do not express FAP, while proliferating normal human melanocytes from fetal, newborn and adult skin and benign nevi express FAP (Rettig et al., 1993; Huber et al., 2003) . Immunohistochemical analysis of human skin lesions showed that FAP is present in a proportion of melanocytic nevi and absent from both primary and metastatic melanoma lesions (Huber et al., 2003) . FAP expression in human melanocytes is abrogated when they undergo malignant transformation and acquire tumorigenic potential and growth factor independence (Rettig et al., 1993) . Overall, these observations reveal that FAP is lost during malignant transformation of proliferating melanocytes, suggesting that its expression may abrogate tumorigenicity.
A second independent observation from studies of somatic cell hybrids between normal fibroblasts and HeLa carcinoma cells identified Fap as a potential inhibitor of tumorigenesis (Tsujimoto et al., 1999) . Fap was one of eight genes differentially expressed in nontumorigenic hybrid lines, consistent with the hypothesis that Fap is involved in suppressing the tumorigenic phenotype. Observations in a third biologic system, Xenopus, support the notion that FAP is a pro-apoptotic factor involved in tissue remodeling. Fap expression was detected specifically in resorbing tadpole tails during amphibian metamorphosis (Brown et al., 1996) .
In this report, we show that FAP has strong tumorsuppressor activity in melanocytic cells, independent of DPPIV. Our results link a molecule whose expression is tightly regulated during early embryonic development and wound healing to activity in tumor suppression, suggesting a role for FAP in checking uncontrolled tissue growth during early development and wound healing. Unexpectedly, our findings also show that the tumor-suppressor activity of FAP is independent of its enzymatic activity, and that point mutants lacking FAP enzymatic activity actually have enhanced tumorsuppressor properties.
Results

Fap is expressed in mouse melanocytes but not melanomas
In human melanocytic cells, expression of both DPPIV and FAP is lost during malignant transformation, concomitant with the gain of growth factor independence and tumorigenicity. Expression of DPPIV and FAP has not been studied in mouse melanocytes. Therefore, we evaluated FAP expression at different stages of mouse melanocyte differentiation (Figure 1a) . The melanoblast line melb-a had undetectable FAP cell surface expression, while in the immature differentiated melan-a2 line, FAP was detected at low levels. The melan-a line, a mature melanocyte line, showed the highest FAP expression, indicating that FAP was expressed in mouse melanocytes and its level of expression correlated with the stage of differentiation. In contrast to human melanocytes, these cells did not express DPPIV on the cell surface.
FAP expression was also assessed in five mouse melanomas from different genetic backgrounds (Figure 1b) . None expressed FAP. However, the protein was detected on mouse embryo fibroblasts (13.5 d.p.c.) used as positive controls. Thus, FAP is expressed by mouse melanocytes but not melanomas, consistent with the notion that FAP is lost during malignant transformation. These results also suggest that FAP is upregulated during melanocyte differentiation, but even JBRH and B16 (data not shown) melanoma cells that correspond to late stages of melanocyte differentiation were FAP-negative.
FAP and FSM, a FAP mutant that lacks enzymatic activity, do not rescue DPPIV cell surface expression
The mouse Fap gene was cloned from C57BL/6 mouse embryonic fibroblasts and a Ser624-Ala mutation in the catalytic domain was generated (Fap serine mutant, FSM). This mutation abrogates both the gelatinolytic and the peptidase activity of FAP (Park et al., 1999) . Both genes were subcloned into tetracycline-inducible vectors and multiple stable transfectants with the respective constructs were generated. Parental B78H1 melanoma cells (a variant of B16 melanoma) were transfected with a control vector pTRE, FAP or FSM, and multiple independent clones were established (a total of seven FAP clones and eight FSM clones analysed). In addition, three independent transfections were performed to ensure that results were reproducible across different transfectants. FACS analysis at different time points of doxycycline induction of FAP/FSM transfectants showed Fap gene product expression in some clones under both uninduced (ÀDOX) and induced ( þ DOX) conditions, indicating that the conditional system was not tightly regulated (data not shown). Switching to a doxycycline-depleted growth medium decreased background Fap expression in uninduced transfected cells and remained inducible.
In human melanocytic cells, expression of human DPPIV rescues human FAP expression and, reciprocally, expression of FAP rescues DPPIV expression (U Wesley and AN Houghton, unpublished data). To determine if the same observation were true in mouse melanocytic cells, mouse DPPIV expression was studied in mouse FAP and FSM transfectants (Figure 2a ). FACS analysis showed FAP expression on the cell surface of wild-type (FAP7) and mutant (FSM12) transfected clones, as well as on mouse embryo fibroblasts (MEF). DPPIV cell surface expression was detected only on fresh mouse thymocytes (positive control). MEF and mouse melanocytes did not express DPPIV, in contrast to human fibroblasts and melanocytes. These results show that DPPIV and FAP expression are uncoupled in mouse cells.
Stable transfectants were tested for dipeptidyl peptidase enzymatic activity after doxycycline induction (Figure 2b ). Clones were analysed by flow cytometry (Figure 2b , histogram inserts) for FAP cell surface expression. Comparable levels of FAP/FSM expression were detected on the cell surface of FAP and FSM transfectants, while both proteins were absent from the control cell lines, pTRE-transfected and B78H1 melanoma. Specific peptidase activity was found in wild-type FAP but not FSM transfectants, which had an activity comparable to vector control pTRE and the parental line B78H1. Thus, a Ser624-Ala substitution in the catalytic domain of FAP extinguished specific peptidase activity of FSM transfectants.
Both FAP and FSM suppress tumorigenicity, but FSM is a more potent tumor suppressor Since FAP expression does not rescue DPPIV expression in mouse melanocytic cells, tumor challenge with mouse FAP transfectants allowed the study of the effect of FAP homodimers in the absence of DPPIV in tumor suppression. C57BL/6 mice were challenged intradermally with syngeneic B78H1 cells transfected with FAP or FSM (Figure 3a ). Mice challenged with FAP or FSM clones showed either no tumor growth or decreased tumor growth with delayed tumor progression. All mice challenged intradermally with vector control pTRE cells developed tumors. The same results were observed after cells were induced in vitro with doxycycline for 72 h.
These results indicate that expression of FAP or FSM abrogated tumorigenicity of B78H1 melanoma cells. The mutant FSM form lacking catalytic activity was a more potent tumor suppressor than wild-type FAP. Also, lack of tumor protection in mice challenged with a mixed population of pTRE þ FAP or pTRE þ FSM (data not shown) was consistent with the tumorsuppressor effect occurring at single cell level (cis effect), that is, FAP/FSM expression on one cell did not impact the tumorigenic phenotype of neighboring cells.
The more potent tumor-suppressor effect of FSM could also be due to immunological recognition of an altered gene product. To discard the possibility that tumor rejection was due to adaptive immune responses against the fap gene product, syngeneic hosts immunodeficient for T-and B-cells (C57BL/6 Rag1 À/À ) were challenged with FAP/FSM transfectants (Figure 3b ). C57BL/6J Rag1 À/À mice were challenged with three different FAP clones, three FSM clones and vector control pTRE transfectants. All mice challenged with pTRE had progressing tumors, while the majority of mice challenged with FAP and FSM clones showed tumor protection that persisted 465 days after challenge. These results indicate that FAP/FSM tumor To show that lack of tumor progression was not simply due to in vitro selection of clones with altered phenotype, the experiment was repeated eight times with clones derived from three independent transfections (Table 1) . FAP and FSM abrogated tumorigenicity and the effect was consistently more potent in FSM transfectants.
Inhibition of tumor growth was not related to the level of FAP expression, and occurred at physiologic levels of expression. For all experiments, 42% of FAP and FSM transfectants expressed FAP/FSM at levels equal to or lower than in normal melanocytes (mean fluorescent intensity (MFI) o 8). There was no correlation between the level of expression of FAP/ FSM by transfectants and the proportion of mice with FAP is a tumor suppressor T Ramirez-Montagut et al were significant (P ¼ 0.01, by Student's t-test). Expression of FAP or FSM was associated with slowing of cell growth.
Of importance, at days 3, 4 and 5 of doxycycline induction, FAP/FSM transfectants reached a plateau in cell number, while vector control pTRE and parental B78H1 maintained incremental growth with no signs of contact inhibition. Visualization of cells grown at high density showed continued growth (Figure 6a , right panel). Vector control pTRE and the parental line B78H1 cells were disorganized, formed clumps, and grew on top of each other. FAP/FSM transfectants still grew in a disorganized manner, but remained in a monolayer, and at high density detached as single cells or in sheets. FAP/FSM transfectants reached a plateau at a density of B1.9 Â 10 3 cells/mm 2 . Growth rates were also assessed by measuring the reduction of tetrazolium into an insoluble formazan dye (data not shown). In these experiments, growth of FAP/FSM transfectants reached a plateau at day 3 of doxycycline induction, while control cells showed continued proliferation without reaching a plateau, the same pattern as the one observed for previous growth curves. Diminished growth of FAP/FSM transfectants at high density as well as growth in a monolayer are consistent with contact inhibition, a characteristic restored by reversing the transformed phenotype.
Since cellular growth requires a constant progression through the cell cycle, to determine if lack of proliferation in FAP/FSM transfectants was due to changes in cell cycle or to cell cycle arrest, nuclear DNA content was determined by propidium iodide staining (Figure 6b ). Cumulative histograms showed that most FAP/FSM transfectant cells but only a small percentage of pTRE and B78H1 cells had 1 Â DNA content. These results indicated that FAP/FSM cell surface expression induced a G0-G1/S arrest, while vector control pTRE and the parental line B78H1 progressed through G1 with the vast majority of their populations in G2/M phase. Growth arrest occurred at low density by 48 h in these experiments.
To determine if FAP/FSM expression had an impact on cell survival, vector control pTRE, the parental line B78H1 and cells transfected with FAP and FSM were cultured in the same medium for up to 6 days (Figure 6c) . At days 4, 5 and 6, adherent and floating cells were collected and stained for FAP expression and for dying cells, determined by TUNEL assay. Treatment of FAP/FSM transfectants with doxycycline for 4 days induced FAP/FSM cell surface expression with little detectable cell death (1-2% TUNEL-positive cells). A significant proportion of FAP/FSM transfectant cells were dying at 5 and 6 days of doxycycline induction (B20-55%), while there was little or no cell death in pTRE and B78H1 controls (B1%) at the same time points.
Most of the clones selected for these in vitro studies were previously used for in vivo experiments (clones FAP4 and FSM3). It was difficult to maintain transfected clones in vitro for more than 1-2 months due to their enhanced susceptibility to cell death. When 
FAP and FSM transfectants are sensitive to depletion of growth/survival factors
To determine if soluble factors (toxic metabolites or cytotoxic factors) could be responsible for cell death, an in vitro Transwell s system was assessed. Two different cellular populations were co-cultured separated by a permeable membrane. At days 7 and 8 post-induction with doxycycline, cells from the upper chamber were analysed for cell death by TUNEL (Figure 7a) . The results showed that FAP transfectants (Figure 7a ; membrane FAP4) underwent apoptosis when cultured with any cell type in the other chamber (lower well containing FAP4 produced 23 and 34% TUNELpositive cells at days 7 and 8, respectively; FSM3, 36 and 52%; and pTRE, 51 and 49%), but not when this lower chamber contained only growth medium (WELL-MEDIUM, 7 and 3% TUNEL-positive at days 7 and 8, respectively). Results with the independent FSM3 transfectants were comparable with those from FAP4 transfectants (data not shown). In contrast, when pTRE transfectants were cultured in the upper chamber (Figure 7a ; membrane pTRE), cells underwent minimal apoptosis (WELL-FAP4, 2 and 4% TUNEL-positive cells at days 7 and 8 is effective; FSM3, 2 and 5%; and pTRE, 2 and 2%). Cell death of pTRE transfectants was slightly increased when cells were absent from the lower chamber (WELL-MEDIUM, 11 and 10%, at days 7 and 8, respectively). A similar proportion of cell death was observed in all upper chambers containing FAP/FSM transfectants independent of the cell type cultured in the lower chamber. As FAP/FSM transfectants underwent apoptosis when pTRE cells were cultured in the lower chamber, these results indicate that apoptosis was not due to a soluble factor being released specifically by FAP/FSM transfectants. These results suggest that apoptosis in FAP/FSM transfectants was induced by stress associated with depletion of growth or survival factors and not by production of soluble cytotoxic molecules.
To confirm whether apoptosis in FAP/FSM transfectants is due to depletion of serum factors, FAP/FSM and vector control pTRE transfectants were kept in the same medium for 6 days, in fresh medium every day (Figure 7b ), or in the same medium supplemented with 10% serum at days 4, 5 and 6 (Figure 7c ). FAP and FSM transfectants left untreated for 6 days show B50-60% cell death. There was little or no cell death in cultures where fresh medium was added every day (Figure 7b ). FAP and FSM transfectants kept in the same medium underwent apoptosis at day 5 (FAP4, 23%; FSM3, 13% TUNEL-positive cells) and day 6 (FAP4, 55%; FSM3 33% TUNEL-positive cells), while vector control cells showed little cell death (o1% TUNEL-positive cells). When cells were kept in the same medium and 10% serum was added at days 4, 5 and 6, there was no cell death in either FAP/FSM transfectants or vector control (o1% TUNEL-positive cells). These results indicate that FAP/FSM transfectants kept in fresh media did not undergo apoptosis and that induction of FAP/FSM cell death was related to stress from progressive depletion of growth/survival factors in the serum.
FAP and FSM expression leads to caspase activation
Since DNA fragmentation is a downstream effect in the caspase-dependent and independent pathways of cell Expression of 25 proteins known to be involved in apoptosis was assessed using Kinetworks protein screens. All proteins were assayed simultaneously to provide a fingerprint of the apoptotic profile for each cell type. Protein profiles were determined in two independent experiments for FAP4, FSM3 and vector control pTRE transfectants induced with doxycycline for 5.5 days. Prior to analysis, the proportion of cell death was determined by caspase activation (Figure 9 , left panels). Of the 25 proteins tested, 18 were detected in at least one sample (Figure 9 , right panels). To establish the differences between protein levels, fold comparisons between FAP4/pTRE and FSM3/pTRE were done after normalization, looking for X1.5-fold differences ( Table 2) . Expression of apoptosis-inducing factor (AIF), p53-induced protein PIGPC1 (PERP), pro-caspase-12 and activated caspase-12 increased in both FAP4 and FSM3 transfectants. Increased levels of AIF imply mitochondrial dysfunction, and activation of caspase-12 points to the presence of endoplasmic reticulum stress. Both pathways (mitochondrial and ER stress) can be activated by serum starvation. Taken together, these results implicate cellular stress with activation of caspases through both mitochondrial and ER stress pathways in cell death of melanoma cells expressing FAP or FSM.
Discussion
Tumors have been called 'wounds that do not heal' to emphasize the biologic similarities of tumorigenesis and wound healing. FAP expression by proliferating melanocytic cells inhibits the malignant phenotype. Expression of FAP at physiologic levels provides a brake for otherwise uncontrolled proliferation and tumorigenicity of transformed melanocytic cells. It appears that melanomas must extinguish FAP expression to become transformed melanocytic cells. Our results implicate a physiological role for FAP as a negative modulator of melanocyte transformation during tissue remodeling. These experiments show that expression of transfected FAP in mouse melanoma cells has a substantial effect on decreasing tumorigenicity and survival of melanoma cells. Although these experiments do not provide direct insight into the role of FAP expression in melanocytes, the observations suggest that FAP downregulates proliferating melanocytes. One condition in which melanocytes are induced to proliferate is during cutaneous wound healing. Therefore, the possible role of FAP in fibroblasts and melanocytes during wound healing needs to be assessed. Two key questions need to be answered. First, how does FAP link to cell cycle and apoptotic pathways in melanoma cells? Secondly, why is the peptidase-deficient form of FAP, FSM, a more potent tumor suppressor?
FAP is an extracellular transmembrane peptidase with a very short intracellular domain (six amino acids), but a large extracellular region comprised of a proximal b-propeller domain and a distal a/b hydrolase fold, Figure 9 Evaluation of proteins involved in apoptosis using Kinetworks screens. Vector control (pTRE), FAP4 and FSM3 transfectants were plated (2 Â 10 6 /flask) and induced with doxycycline for 5.5 days. Apoptosis was determined by caspase activation (flow cytometry insets) and percentages are shown in the upper right corner. Cell lysates were assayed in duplicate for 25 different proteins involved in programmed cell death. The gels present results of Kinetworkst protein screens from one of two experiments Figure 8 Implicating caspase activation in apoptosis of FAP/FSM transfectants. Caspase activation was determined by a FITClabeled pan-caspase inhibitor (Caspatag s ) at days 3, 4, 5 and 6 of doxycycline induction. Histograms show caspase activation at day 6 of doxycycline induction where the catalytic triad resides (Cheng et al., 2002) . Wild-type FAP and mutated FAP (FSM) both promote cell death upon cell stress, indicating that increased susceptibility to cell death is independent of the serine protease enzymatic activity. Therefore, it is possible that induction of apoptosis depends on the b-propeller domain perhaps through interaction with other proteins.
A subtle but notable difference in the profile of apoptotic proteins was observed between FAP and FSM transfectants. AIF and PERP were upregulated in both FAP and FSM transfectants, but the levels were significantly different between them. FAP transfectants showed a marked increase in AIF. This suggests that lack of survival factors in wild-type FAP transfectants leads primarily to mitochondrial dysfunction with AIF release and caspase-12 activation. Meanwhile, FSM transfectants showed stronger PERP induction, suggesting additional activation through a p53-dependent pathway. One speculation is that lack of serine protease activity slowed degradation of residual survival/growth factors. Thus, FSM-positive cells could be less tumorigenic because they have activated a second intact tumorsuppressor pathway through p53.
Although the tumor-suppressor effect of FAP may seem contradictory to its extensive expression in tumor stroma, we propose a model that reconciles both observations. Our experiments demonstrate that FAP expression slows growth and decreases the threshold for cell death under stress conditions. FAP is not expressed in resting epidermal melanocytes but is upregulated when these cells are activated to proliferate (Rettig et al., 1993) . Consistent with these observations, common melanocytic nevi, which are hyperplastic lesions of melanocytes, express FAP (Huber et al., 2003) . During wound healing, melanocytes proliferate and migrate into the epithelium to reconstitute pigmentation and other melanocyte functions. Melanocyte hyperplasia in the epidermis occurs not infrequently in epithelia following wound healing, but melanomas very rarely arise at these sites.
Since FAP expression is highly restricted to activated melanocytes and fibroblasts , we speculate that the cellular function of FAP in melanocytes and fibroblasts might be similar. One possibility is that FAP expression may provide negative feedback control to regulate otherwise uncontrolled proliferation of activated melanocytes and fibroblasts during tissue remodeling, recognizing that an individual protein can have distinct functions in different cell types. For instance, in the setting of stroma of wound healing, it is known that myofibroblast survival depends on survival factors provided by the inflammatory process (Tuxhorn et al., 2001) . During resolution of wound healing, activated myofibroblasts undergo cell death as part of tissue-remodeling, due to withdrawal of inflammatory/growth factor signals (Desmouliere, 1995) . We wonder whether the tissue remodeling stage of wound healing, which involves apoptosis induced by survival factor depletion in myofibroblasts, is dependent on FAP expression. We emphasize that these conjectures are unproven and highly speculative, and we are presently addressing these possibilities experimentally.
Materials and methods
Mice and antibodies
C57BL/6 (6-8 weeks old, female) and C57BL/6J-Rag1 tm1Mom mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) or National Cancer Institute (NCI) Plasmids, gene cloning and site-directed mutagenesis Plasmids pTRE1 and Tet-ON were purchased from Clontech, Palo Alto, CA, USA. The mouse fap gene was cloned by RT-PCR from a C57BL/6 melanoma lesion. Site-directed mutagenesis was used to generate FSM. The methylated plasmid encoding fap was replicated with FSM primers for o10 PCR cycles. The mixture of template DNA, newly synthesized DNA and hybrid parental/newly synthesized DNA was treated with Dpn I. This enzyme digests the in vivo methylated parental template and hybrid DNA. The resulting PCR product (a plasmid encoding FSM) was transformed into Escherichia coli. The FAP and FSM constructs were subcloned into pTRE1 at EcoRI sites.
Transfection and isolation of stable transfectants
A dose curve of resistance to the antibiotic geneticin (G418) (Gibco BRL Life Technologies, Grand Island, NY, USA) determined that 0.8 mg/ml induced 50% death of B78H1 cells at day 5 and 100% death at day 10.
Stable transfectants were obtained by plating 5 Â 10 5 cells in 100-mm Petri dishes. Prior to cotransfection, cells were washed in serum-free medium and were incubated with 5 and 10 mg of Tet-ON:pTRE diluted 1 : 10 in the presence of 25 ml lipofectamine reagent (Invitrogen Corporation, Carlsbad, CA, USA) for 4-6 h. Cells were washed and incubated overnight in complete medium. Selection medium (0.8 mg/ml G418) was added 48 h after transfection and, 10 days later, when mock transfectants revealed 100% death, colonies assumed to represent a single clone were transferred using cloning rings (Bellco, Vineland, NJ, USA) into the wells of 24-well plates. Protein expression was evaluated based on flow cytometry assays.
Dipeptidyl peptidase enzyme assay for fap transfectants
Cell samples were incubated in lysis buffer (20 mM HEPES, 2 mM EDTA, 1.5 mM. MgCl 2 , 10 mM KCl, 0.1% NP40) on ice for 30 min. Pellets were obtained by centrifugation (14 000 r.p.m. for 8 min), the supernatant was discarded and the pellet was resuspended in CHAPS buffer (1% CHAPS [3-[3-cholamidopropyl] dimethyl-ammonio-1-propanesulfonate], 50 mM Tris, 150 mM NaCl, pH 8.6) and incubated on ice for 30 min. After centrifugation (14 000 r.p.m. for 8 min), enzymatic activity was measured in supernatant lysates. In all, 30 ml of supernatant lysates was incubated with 10 ml of 10mM substrate, Gly-Pro p-nitroanilide (Sigma, St Louis, MO, USA), at 371C for 30 min. Reactions were stopped with 250 ml 10% TCA, and the supernatants were mixed with 250 ml 0.1% NaNO 2 and incubated at room temperature for 3 min, followed by addition of 250 ml 0.5% ammonium sulfamate. At the end of a 2-min incubation, 500 ml 0.05% N-(1-naphthyl) ethylenediamine was added, and released p-nitroaniline was measured at 540 nm. Peptidase activities were standardized based on protein concentration and also on cell number. Protein concentrations were measured by Bradford assay using the BioRad DC protein assay kit. Specific activities were expressed as picomoles per microgram protein per minute.
FACS analysis
Cells were plated at a concentration of 0.5 Â 10 6 /ml and in PBS supplemented with 5% bovine serum albumin (Sigma, St Louis, MO, USA) and 5% goat serum (Invitrogen Corporation, Carlsbad, CA, USA) (PBS-FACS). Cells were stained with 0.5-2 mg of monoclonal antibody of interest for 30 min-1 h on ice. After washing cells twice, where needed, a FITC-or PE-secondary antibody was added and cells were incubated for an additional 30 min-1 h in PBS-FACS. Cells were washed twice and fixed with 1-2% paraformaldehyde prior to analysis by FACScant (Becton Dickinson).
Tumor challenge C57BL/6 mice were shaved on the flank and injected intradermally with 1x10 6 B78H1 transfected cells. After challenging, tumor size was monitored by measuring mice three times a week. Mice were killed when tumor reached 2 cm in diameter.
Growth assays
Growth curves were determined as described (Houghton et al., 1987) . In brief, cells were plated at a density of 1 Â 10 4 cells per well in triplicate in 24-well plates. Every 3 days, cultures were replenished with fresh media. Cells were trypsinized daily for 4-7 days, stained with Trypan blue, and viable cells were counted. Doubling time was determined from a least-squares regression fit of log cell number vs time during the logarithmic growth phase. Growth was additionally measured by reduction of the MTT dye (Sigma, St Louis, MO, USA). Cells (1 Â 10 4 ) were incubated with 10 mg MTT for 4 h at 371C. Cells were washed twice with PBS. Formazan production was measured in a colorimetric assay at 570 nm by adding 200 ml of DMSO (Sigma, St Louis, MO, USA) per well.
Apoptosis and cell cycle analysis
For apoptosis assays, medium was not refreshed (unless specified) for 3-8 days. Cell death was measured by TdTmediated dUTP-biotin nick-end labeling (TUNEL) assay using the ApopTag kit. Caspase activation was detected using the CaspaTag s caspase activity kit (Intergen Co., Purchase, NY, USA). Proportions of apoptotic cells were calculated by FACScant (Becton Dickinson). For cell cycle analysis, cells were permeabilized, treated with RNAase and DNA content was determined with propidium iodide (Sigma, St Louis, MO, USA). 
